Shares of Johnson & Johnson (NYSE:JNJ) Struck With Upgrade From Barclays. Should Investors Now Buy the Stock?

Share

Johnson & Johnson (NYSE:JNJ) Stock Upgrade

Stock research analysts at Barclays’s stock research division upgraded the rating on shares of Johnson & Johnson (NYSE:JNJ) from a “Equal Weight” to a “Overweight” earlier today. The analysts now have a $115 TP on JNJ or a 12.41% upside.

From a total of 16 analysts covering Johnson & Johnson (NYSE:JNJ) stock, 10 rate it a ”Buy”, 1 a “Sell”, and 9 a ”Hold”. This means that 50% of the ratings are positive. The highest target price is $119 while the lowest target price is $90. The mean of all analyst targets is $109 with a 7.08% above today’s ($102.29) stock price. Johnson & Johnson was the topic of 13 analyst reports since August 7, 2015 according to the firm StockzIntelligence Inc. Barclays Capital upgraded shares on December 1 to “Overweight” rating. Vetr downgraded shares to “Strong-Buy” rating and $106.73 target share price in a report from an August 31. RBC Capital Markets maintained JNJ stock in a recent report from October 7 with “Outperform” rating. Cowen & Co maintained the rating on August 25. Cowen & Co has a “Outperform” rating and a $114 price target on shares. Finally, Deutsche Bank upgraded the stock to “Buy” rating in a report issued on a September 29.

Approximately 3.72 million shares of stock traded hands. Johnson & Johnson (NYSE:JNJ) has risen 0.50% since April 28, 2015 and is uptrending. It has outperformed by 2.12% the S&P500.

Johnson & Johnson is a holding company. The company has a market cap of $285.57 billion. The Firm is engaged in the research and development, manufacture and sale of a range of products in the health care field. It has 19.6 P/E ratio. The Firm has more than 265 operating companies conducting business around the world.

According to Zacks Investment Research, “Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women’s health fields, nutritional and over-the-counter pharmaceutical products. The company’s Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women’s health products. Johnson & Johnson is based in New Brunswick, New Jersey.” Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

COMMENTS: